Research Papers:
Doxorubicin-triggered self-assembly of native amphiphilic peptides into spherical nanoparticles
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2502 views | HTML 2977 views | ?
Abstract
Xiaobo Fan1,2,*, Fengfeng Zhao2,*, Xiyong Wang2, Guoqiu Wu1,2
1Center of Clinical Laboratory Medicine of Zhongda Hospital, Southeast University, Nanjing, 210009, China
2Medical School, Southeast University, Nanjing, 210009, China
*These authors have contributed equally to this work
Correspondence to:
Guoqiu Wu, email: [email protected]
Keywords: matrilin-1 C-terminal peptide, self-assembly, nanosphere, drug delivery, cancer therapy
Received: May 16, 2016 Accepted: July 19, 2016 Published: August 11, 2016
ABSTRACT
In this study, we designed and fabricated self-assembly nanospheres, which consisted of a P45 peptide and doxorubicin (Dox). P45 is a hybrid peptide composed of an Arg-Gly-Asp motif linked to the human matrilin-1 C-terminal domain by a serine linker. The fabricated nanospheres had a uniform mulberry-like spherical shape, a diameter of 63 nm, excellent polydispersity, and high Dox drug-loading efficiency. In the presence of the RGD motif, the Dox/P45 nanospheres could specifically target A549 cells, which have high integrin αvβ3 expression. Confocal laser scanning microscopy and flow cytometry results showed the enhanced cellular uptake of Dox/P45, and the CCK8 assay indicated the low cytotoxicity of the nanospheres to normal human embryonic kidney 293 cells. Furthermore, the fabricated nanospheres were stable in a physiological environment, but they disassembled and exhibited a rapid Dox release in an acidic atmosphere, allowing for a specific pH-sensitive release into cytosol after cellular uptake. These results suggest that natural amphiphilic peptides can be used as carriers of nanodrugs for targeting delivery as well as controlled drug release for cancer therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11213